Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/20—Bacteria; Culture media therefor
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P21/00—Preparation of peptides or proteins
  • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
  • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the field of the production of proteins or polypeptides using recombinant DNA technology. More specifically, the present invention relates to a method for the exocrine expression of Escherichia coli to produce a lysostaphin enzyme. Background technique
• the lysostaphin enzyme was first discovered in 1964 by Schindler and Schuhard in the culture of Staphylococcus simulans (US Patent No. 3,278,378; 1966), having a molecular weight of 27 kDa and containing 246 amino acids. Its mechanism of action is to cleave the glycine pentapeptide bond bridge in the staphylococcal cell wall peptidoglycan, thereby destroying the integrity of the cell wall and dissolving the cell, which is an endopeptidase.
• the gene for lysostaphin was expressed in bacteria such as Escherichia coli, Bacillus subtilis and Bacillus sphaericus by molecular cloning methods.
• the staphylococcal cell wall can be rapidly lysed at a lower drug concentration, and the antibacterial effect is fast, the antibacterial activity is strong, the resistant strain is not easily induced, and the antibacterial spectrum is specific.
• high-purity recombinant lysostaphin enzymes have been produced on a large scale at home and abroad, and have been commercialized, and are widely used in bacteriology, disinfection, enzymology research, and clinical antibacterial therapy.
• Prg5 was transformed into E. coli JM105.
• Pjp pDF8, pRP1 were transformed into a large number of Bacillus (Bacillus subtilis BD170, Bacillus sphaeri 00), and the resulting lysostaphin enzyme was identified by immunization, electrophoresis and lysostaphin produced by S.
• the lysostaphin enzyme (150 mg/L) is 5 times that of SM/ims.
• the patent also provides a 1.5 kb DNA sequence encoding a 389 amino acid pre- lysostaphin precursor protein which is translated into a mature lysostaphin enzyme after translation. In recent years, it has been found that the N-terminus of the enzyme is heterogeneous, and most of it is 2 alanine less than the wild type.
• the expressed lysostaphin enzyme is stored in the cells in the form of insoluble inclusion bodies, and the cells must be broken before they can be separated.
• Protein denaturation agents should be used in the separation process, and finally the proteins should be renatured. Many molecules will be mis-formed during the renaturation process.
• the molecules with abnormal structure, at the same time, the residual protein of the bacteria is a substance that is difficult to be removed during the production of genetic engineering drugs, which easily affects the quality of the product.
• the technical problem to be solved by the present invention is to provide a method for efficiently exogenously expressing Escherichia coli enzyme in Escherichia coli to overcome the shortcomings of the prior art.
• the inventive concept of the present invention is such that lysostaphin has been found since the 1960s, and since the enzyme has a very good bactericidal effect against Staphylococcus aureus, particularly resistant Staphylococcus aureus, it has been carried out at home and abroad. Human medicinal research, and try to declare new drugs. However, since the recombinant lysostaphin enzyme has been expressed by B. sphaericus, the engineered bacteria have not yet been approved for use in medicines, and the expression host bacteria currently used as human drugs are mainly Escherichia coli and yeast, and thus the world researchers in various countries are trying to solve this problem in order to apply for new drugs.
• the present invention attempts to insert a signal peptide sequence secreted and expressed in Escherichia coli before the coding sequence of the mature lysostaphin enzyme to complete the extracellular secretion of the mature lysostaphin enzyme in E. coli.
• the technical solution of the present invention is as follows:
• the invention provides a method for exogenously expressing E. coli lysostaphin enzyme, comprising the following steps:
• the lysostaphin enzyme is consistent with the wild-type lysostaphin enzyme sequence, and includes mutants thereof, such as two alanines at the N-terminus. .
• the signal peptide therein is one of O m p A, phoA, Lysn, and pdB.
• the amino acid sequence of the OmpA signal peptide is as follows - SEQ.ID.NO:3: MKXTAIAIAV ALAGFATVAQ A
• amino acid sequence of the p oA signal peptide is as follows:
• SEQ.ID.NO:5 M MSLFQ hire KSKLLPIAAV SVLTAGIFAG A
• the amino acid of the Lysn signal peptide is as follows:
• SEQ.ID.NO:6 MKKTK NYYT RPLAIGLSTF ALA
• amino acid sequence of the pelB signal peptide is as follows:
• SEQ.ID.NO:7 MKRLCLWFTV FSLFLVLLPG KALG
• the expression of the lysostaphin enzyme in step (2) is induced expression.
• the vector described above is a vector for expression of Escherichia coli, and may be one of pUC series, pET series or pGEX series, or may be pBV220.
• the promoter may be one of the T7 promoter, the PlPr promoter or the 1 ac UV 5 promoter.
• the specific steps are: first, synthesize a pair of suitable primers, and then use the total DNA of Staphylo's s Simulans (NRRL B-2628) as a template, and use the pyrobest enzyme (a high-fidelity DNA polymerase) to dissolve by PCR.
• the sequence of the staphylococcal enzyme is selectively amplified.
• the amplified product was detected and recovered by electrophoresis on an agarose gel containing ethidium bromide, and the purified amplified product was digested with Ndel and Hindlll.
• Enzyme-cleaved fragments were treated with T4 DNA ligase
• the vector digested with Ndel and Hindlll was also ligated at 16 ° C for 2 hours, i.e., after ligating the ribosome binding site of the vector, the ligated solution was transformed into E. coli to obtain a recombinant plasmid.
• the recombinant plasmid was sequenced by an automatic DNA sequencer, and sequence comparison confirmed that the obtained DNA sequence was identical to the known gene sequence encoding the signal peptide and the mature lysostaphin enzyme.
• the recombinant plasmid was transformed into E. coli. Positive clones were picked and inserted into 50 ml of LB liquid medium (containing 30 mg/ml kanamycin). 37 ⁇ shaking culture, cultured until the optical density value (wavelength 600 nm) was 0.6, then IPTG was added to a final concentration of 0.05 mM induced protein. The expression was continued for 3 hours, the fermentation broth was centrifuged, and the supernatant was assayed for lysostaphin activity by colorimetry.
• the method for efficiently excreting and expressing E. coli of Escherichia coli provided by the invention has the advantages that the expression product is present in the culture medium in the form of the final mature lysostaphin, without renaturation of the inclusion body;
• the purification is simple, the host protein is less polluted; the recovery rate is high, the expression amount can reach 200-400 mg/L, and the recovery rate is greater than 60%.
• Figure 1 shows the mature lysostaphin gene amplified from the total DNA of Staphylococus Simulans (NRRL B-2628).
• Lane 1 The total DNA of Staphylococus Simulans (NRRL B-2628) is a template, and the bands of the amplified products obtained by SEQ.ID.NO:l and SEQ.ID.NO:2 are a pair of primers, and the size is 887 bp.
• Lane M protein molecular weight Marker
• Figure 2 shows the construction of a recombinant lysostaphin enzyme expression vector
• Figure 3 shows the purified lysostaphin SDS-PAGE electrophoresis
• Lane B Western blot
• Example 1 Construction of a recombinant lysostaphin-secreting expression vector, i.e., a clone of an OmpA signal peptide and a mature lysostaphin fusion gene.
• SEQ.ID.NO:l 5'- rCGCTACmTmCT ⁇ GGCTG TGCAACACATGAACATTCAGCAC ⁇
• SEQ.ID.NO:2 5'-CCA 4GCri €AACTTTAGGAATGAG-3'
• SEQ.ID.NO: 1 and SEQ.ID.NO:2 as a pair of primers, using pyrobest enzyme (a high-fidelity DNA polymerase), The sequence of the lysostaphin enzyme is selectively amplified by a PCR method. The amplified product was detected and recovered by electrophoresis on an agarose gel containing ethidium bromide.
• M represents the molecular weight marker lane
• lane 1 shows ⁇ I Staphy cocus Simulans (NKRL B-2628)
• the total DNA was a template, and the bands of the amplified products obtained by SEQ.ID.NO:l and SEQ.ID.N0:2 were a pair of primers, and the size was 887 bp.
• the amplified product after purification and recovery was digested with Ndel and Hindlll.
• the digested fragment was ligated with T4 DNA ligase and the pET30a vector digested with Ndel and Hindlll for 2 hours at 16 ° C, ie, after ligating the ribosome binding site of the pET30a vector, as shown in Fig. 2, the ligating solution
• the recombinant plasmid pET-OmpAlss was obtained by transforming Escherichia coli DH5a.
• the recombinant plasmid was sequenced by an automatic DNA sequencer, and sequence comparison confirmed that the obtained DNA sequence was identical to the known gene sequence encoding the OmpA signal peptide and the mature lysostaphin enzyme.
• the constructed recombinant plasmid pET-OmpAlss encodes the amino acid sequence of the OmpA signal peptide as follows: SEQ.ID.NO:3: MKKTAIAIAV ALAGFATVAQ A
• the constructed recombinant plasmid pET-OmpAlss encodes the amino acid sequence of the mature lysostaphin enzyme as follows -
• SEQ.ID.NO:4 AATHEHSAQW L YK GYGY GPYPLGINGG MHYGVDFFMN IGTPVKAISS GKIVEAGWSN YGGGNQIGLI ENDGVHRQWY MHLSKY VKV GDYVKAGQII GWSGSTGYST APHLHFQRMV NSFSNSTAQD PMPFLKSAGY GKAGGTVTPT PNTGWKTNKY GTLYKSESAS FTPNTDIITR TTGPF SMPQ SGVLKAGQTI HYDEVMKQDG HVWVGYTGNS GQRIYLPVRT WNKSTNTLGV LWGTIK
• Example 2 Establishment of secreted expression engineered strain of recombinant lysostaphin enzyme
• the recombinant plasmid pET-OmpAlss was transformed into E. coli TOP10, JM109 (DE3), BL21 (DE3) o, respectively, and positive clones were picked and inserted into 50 ml of LB liquid medium ( The medium containing 30 mg/ml kanamycin was shaken at 37 ° C, and cultured until the optical density value (wavelength 600 nm) was 0.6. Then, IPTG was added to a final concentration of 0.05 mM to induce protein expression, and the culture was continued for 3 hours, and the fermentation broth was centrifuged. The supernatant was assayed for lysostaphin activity by colorimetry.
• the lysostaphin expression activities of TOP10, JM109 (DE3) and BL21 (DE3) containing the recombinant plasmid pET-OmpAlss in Example 2 were determined by colorimetry.
• the specific determination methods were as follows:
• Quantitative detection of lysostaphin enzymes by colorimetric method coupled with KR brilliant blue dye-based S. aureus cell wall peptidoglycan (K R-PG) as a color source substrate, according to the quantitative release of the band during the action of the enzyme
• K R-PG KR brilliant blue dye-based S. aureus cell wall peptidoglycan
• Color source substrate K R- PG prepared by our company, uniformly suspended in a ratio of 1:5 (m/v) with 0.2mol/L Gly-NaOH buffer ( ⁇ , ⁇ ), and used as a spare;
• Glycine and sodium hydroxide are of analytical grade and formulated into 0.2mol/L Gly-NaOH buffer (pHlO.0);
• Tris formulated into 0.05mol/L Tris-HCl buffer (pH7.5);
• the lysostaphin enzyme reference material After the lysostaphin enzyme reference material has been calibrated, it is stored at -20 ° C. One tube is taken out before use, and accurately dissolved in 1.0 ml of 0.05 mol/L Tris-HCl buffer (pH 7.5) to prepare 90.0 U/ml. The lysostaphin reference solution was immediately dispensed into several Eppendorf tubes, 50ul per tube, immediately stored in a refrigerator below -30 °C. Take 1 tube before use and add 450iil 0.05mol/L Tris-HCl buffer. The solution (pH 7.5) was diluted to a 9.0 U/ml reference solution. Use 1 for each test to avoid repeated freezing and thawing.
• Tris-HCl buffer pH 7.5
• test sample was measured in the same manner as the standard curve. After the sample was pre-diluted with a 0.05 mol/l Tris-HCl dilution (pH 7.5), 50 ul was taken for measurement, and each sample was made into 2 parallel tubes, and the results were averaged.
• C is the measured value of the sample (U/ml)
• N is the dilution factor of the sample
• CO is the original sample activity (U/ml)
• 0.9 is the reaction system volume (ml)
• 0.05 is the sample addition volume (ml).
• the lysostaphin expression activities of TOP10, JM109 (DE3), and BL21 (DE3) containing the recombinant plasmid pET-OmpAlss were 56 U/ml, 45 U/ml, and 70 U/ml, respectively.
• the TOP 10 containing the recombinant plasmid pET-OmpAlss was added to 50 ml of LB liquid medium (containing 30 mg/ml kanamycin) and cultured at 37 ° C for 16 hours with shaking, and then transferred to 3 liters of LB medium (containing 30 mg/ml card).
• 37 ⁇ was shaken for 5 hours, IFTG was added to a final concentration of 0.05 mM, and the culture was continued for 3 hours to induce protein expression; the fermentation broth was purified by centrifugation, cation purification, hydrophobic chromatography, gel filtration to obtain a purity greater than that.
• the purified lysostaphin enzyme was subjected to SDS-PAGE electrophoresis and western blot, as shown in Fig. 3 and Fig. 4, wherein lanes 1 to 4 were: fermentation supernatant, cation-purified sample, hydrophobic chromatography sample, gel filtration After the sample, Lane 5 is a Sigma lysostaphin sample and Lane M is a low molecular weight Marker. Lanes 6 to 9 are western blots; The purified lysostaphin enzyme has a molecular weight of 26,927 Da by MALDI-TOF (Fig. 5) and is very close to the theoretical molecular weight of 26,924 Da, and is also close to the molecular weight of Sigma's lysostaphin enzyme of 26,912 Da.
• the purified lysostaphin enzyme was determined by the N-terminal amino acid residue: N-terminal 15 amino acids
• the sequencing result was identical to the natural lysostaphin enzyme, which was AATHEHSAQWLNNYK.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Medicinal Chemistry (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Tropical Medicine & Parasitology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Enzymes And Modification Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37656277

Family Applications (1)

Country Status (6)

Cited By (2)

Families Citing this family (15)

Citations (4)

Family Cites Families (9)

• 2005
  • 2005-07-22 CN CNB2005100280380A patent/CN100475965C/zh not_active Expired - Fee Related
• 2006
  • 2006-07-11 CN CN2006800268150A patent/CN101228271B/zh active Active
  • 2006-07-11 KR KR1020087001751A patent/KR101098353B1/ko active Active
  • 2006-07-11 EP EP20060761397 patent/EP1918369B1/en active Active
  • 2006-07-11 JP JP2008521775A patent/JP5242388B2/ja active Active
  • 2006-07-11 WO PCT/CN2006/001640 patent/WO2007009351A1/zh not_active Ceased
  • 2006-07-11 US US11/995,735 patent/US8241901B2/en active Active

Patent Citations (4)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events